UnknownNot Applicable

Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension

Greece60 participantsStarted 2015-03-12

Plain-language summary

The objective of the present study is to assess blood coagulation disorders in patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. The investigators aim to evaluate any possible coagulation abnormalities related to the patients' primary disease and any possible effects the pulmonary hypertension- specific therapy may have on hemostasis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pulmonary Arterial Hypertension, * Chronic Thromboembolic Pulmonary Hypertension. Exclusion Criteria: * renal insufficiency, * hepatic insufficiency, * thyroid dysfunction, * malignancy, * active infections, * receiving anticoagulant or antiplatelet therapy, * history of hemostatic disorders irrelevant to their primary disease, * abnormal red blood counts.

What they're measuring

PFA-100 in detection of platelet abnormalities in PAH and CTEPH patients.

Timeframe: 6 months

Light transmission aggreggometry in detection of platelet abnormalities in PAH and CTEPH patients.

Timeframe: 6 months

ROTEM in detection of coagulation abnormalities in PAH and CTEPH patients.

Timeframe: 6 months

Endogenous thrombin potential in detection of thrombin abnormalities in PAH and CTEPH patients.

Timeframe: 6 months

Trial details

NCT IDNCT03195543

SponsorNational and Kapodistrian University of Athens

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-12

Contact for this trial

Eleni Vrigkou, MD, MSc

00302105832179 elenivrigkou@gmail.com

View on ClinicalTrials.gov More Pulmonary Artery Hypertension trials